In bladder cancer (BLCA) there are, to date, no reliable diagnostics available to predict the potential benefit of a therapeutic approach. The extraordinarily high molecular heterogeneity of BLCA might explain its wide range of therapy responses to empiric treatments. To better stratify patients for treatment response, we present a highly automated workflow for in-silico drug response prediction based on a tumor's individual multi-omic profile. Within the TCGA-BLCA cohort, the algorithm identified a panel of 21 genes and 72 drugs, that suggested personalized treatment for 94,7% of patients - including five genes not yet reported as biomarkers for clinical testing in BLCA. The automated predictions were complemented by manually curated data, thus allowing for accurate sensitivity- or resistance-directed drug response predictions. Manual curation revealed pitfalls of current, and potential of future drug-gene interaction databases. Functional testing in patient derived models and/or clinical trials are next steps to validate our in-silico drug predictions. ### Competing Interest Statement Three authors (EG, YL, ED) are employees of GenomeDx Biosciences, which provided the drug re-sponse scores in the TCGA BLCA cohort. The remaining authors have no direct or indirect commer-cial financial incentive associated with publishing the article.

Download data

• Downloaded 201 times
• Download rankings, all-time:
  • Site-wide: 97,146
  • In bioinformatics: 8,420
• Year to date:
  • Site-wide: 64,222
• Since beginning of last month:
  • Site-wide: 110,092

Altmetric data

Downloads over time

Distribution of downloads per paper, site-wide